182234-10-2

Basic information

• Product Name: 1H-Indol-4-amine,2-methyl-(9CI)
• Synonyms: 1H-Indol-4-amine,2-methyl-(9CI);4-AMino-2-Methyl-1H-indole;2-Methyl-1H-indol-4-ylamine;2-Methyl-1H-indol-4-amine
• CAS NO: 182234-10-2
• Molecular Formula: C₉H₁₀N₂
• Molecular Weight: 146.1891
• Product Categories: AMINEPRIMARY
• Mol File: 182234-10-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indol-4-amine,2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indol-4-amine,2-methyl-(9CI)(182234-10-2)
• EPA Substance Registry System: 1H-Indol-4-amine,2-methyl-(9CI)(182234-10-2)

Safety Data

• Hazardous Substances Data: 182234-10-2(Hazardous Substances Data)

Usage

General Description

1H-Indol-4-amine, 2-methyl-(9CI) is a chemical compound with the molecular formula C9H10N2. It is a derivative of indole, which is a heterocyclic aromatic organic compound. The compound contains an indole ring with an amine group and a methyl substituent at the 2-position. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also used in research and development as a reagent and intermediate in organic synthesis. The compound has potential biological activities and is of interest in medicinal chemistry for its potential pharmacological properties.

Upstream product

• 3484-10-4 2-methyl-4-nitro-1H-indole 
• 99-09-2 3-nitro-aniline 
• 1537216-85-5 4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-methyl-1H-indole 

Downstream Products

• 1262797-37-4 3-(2-methyl-1H-indol-4-ylamino)-3-phenyl-acrylic acid ethyl ester 

Relevant articles and documents

Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors

Valine-containing protein (VCP) is a member of the adenosine triphosphate family involved in a variety of cellular activities. VCP/p97 is capable of maintaining protein homeostasis and mediating the degradation of misfolded polypeptides by the ubiquitin–proteasome system (UPS). In this manuscript, a series of novel p97 inhibitors with pyrimidine as core structure were designed, synthesized and biologically evaluated. Based on the enzymatic results, a detailed structure–activity relationship discussion of the synthesized compounds was carried out. Furthermore, cellular activities of the compounds with enzymatic potency of less than 200 nM were investigated by using A549 and RPMI8226 cell lines. Among the screened inhibitors, compound 17 (IC50, 54.7 nM) showed good enzymatic activity. Investigation of cellular activities with non-small cell lung cancer A549 and multiple myeloma (MM) RPMI8226 further confirmed the potency of 17 with the IC50 values of 2.80 μM and 0.86 μM, respectively. Compound 17 is now being developed as a candidate. Finally, docking studies were carried out to explore the possible binding mode between the active inhibitor 17 and p97.

Synthesis, in vitro and in vivo preliminary evaluation of anti-angiogenic properties of some pyrroloazaflavones

This work investigated the in vitro and in vivo anti-angiogenic activity of some pyrroloazaflavones, exactly 2-phenyl-1H-pyrrolo[2,3-h]quinolin-4(7H)ones, with vinblastine as reference compound. Growth inhibitory activity, migration, and capillary-like structures formation were determined in human umbilical vein endothelial cell cultures, and Matrigel plug assay was carried out to evaluate in vivo effects on angiogenesis. Collectively, our results indicate that some pyrroloazaflavone derivatives, at non-cytotoxic concentrations and like vinblastine are able: (i) to exert in vitro anti-angiogenic activity and (ii) to counteract in vitro and in vivo the pro-angiogenic effects of fibroblast growth factor-2 (FGF-2).